Evidence map›Paper›PMID 40883027›Full record

ArticleCancer genomics & proteomics

Programmatically Efficient Separation of Immune Infiltrate and Tumor Gene Expression Overlap Potentials in a Big Data Setting: FASLG Gene Expression-related Survival Distinctions.

Elizabeth A Fletcher, Toriana R Dabkowski, Mallika Varkhedi, George Blanck

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth A FletcherDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Toriana R DabkowskiDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
Mallika VarkhediDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, U.S.A.; gblanck@usf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTypically expressed on T-cells and NK cells, FASLG induces apoptosis in target cells upon binding Fas. However, assessing potential FASLG expression in tumor cells with convenient genomics approaches has been challenging. MATERIALS AND

methodsThis study applied a novel assessment of FASLG copy numbers (CNs) and gene expression levels, applicable to bulk exome and RNAseq files.

resultsAnalyses indicated high FASLG CN associated with worse survival outcomes. Interestingly, higher FASLG gene expression was found to be associated with better survival outcomes, which led to a determination of whether this result was due to FASLG expression from tumor-infiltrating lymphocytes (TILs) instead of cancer cells demonstrating the higher CNs. In fact, T-cell markers CD4 and CD8A highly correlated with FASLG expression, consistent with the hypothesis that the high FASLG expression was associated with the TILs. Subsequent analyses confirmed that CN increases led to increased gene expression in the genomic region of the FASLG gene, particularly with an assessment of the expression of the neighboring PRRC2C gene. In sum, FASLG CN assessments, even independently of a corresponding gene expression correlation, may provide important characterizations of tumor cells.

conclusionThis study indicates that FASLG CN increases could represent a mechanism of tumor escape from TILs and a prognostic indicator; and tumor FASLG may be a suitable drug target for reducing tumor evasion of T-cells.

Indexed as

Fas Ligand ProteinGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingNeoplasmsBiomarkers, TumorHumansPrognosisBiomarkers, TumorFASLG protein, humanFas Ligand Proteinbreast cancerBurkitt lymphomaFASLGsurvival probability distinctionsT-cell infiltrate

Identifiers

PMID40883027
PMCPMC12402715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.